Particle.news
Download on the App Store
9 ARTICLES
·
last wk.

U.S. Eases Pharma Tariff Threat as Pfizer Agrees to Price Cuts and $70 Billion U.S. Investment

Tariff relief tied to price benchmarks signals a turn toward negotiated deals over blanket duties.

Image
Ein Pfizer-Logo ist an einem Forschungszentrum des Unternehmens in San Diego zu sehen.
Image
Image

Overview

  • Pfizer will lower prices in Medicaid and peg launch prices of new medicines to the lowest rates in comparable wealthy countries under a most‑favored‑nation model.
  • CEO Albert Bourla said Pfizer will invest $70 billion in U.S. production, research and development and receive a three‑year exemption from proposed Section 232 drug tariffs if manufacturing shifts to the U.S.
  • The White House is preparing a TrumpRx website for direct purchases of prescription drugs, with officials touting large discounts and citing specific Pfizer products, though launch details remain developing.
  • German media citing a senior U.S. official report that previously floated 100% tariffs on branded drug imports will not be imposed for now as talks with manufacturers proceed.
  • Pfizer described the agreement’s terms as confidential, the administration is pressuring other companies to follow, and Pfizer shares rose after news of the deal.